Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Lots for you today from the 2023 STAT Summit. Our podcast came live from the rollicking Boston affair, and we heard from plenty of the field’s top players. This includes Biogen CEO Chris Viehbacher, who spoke of how the company wants to move forward in a more disciplined fashion. We also talk about why Beam Therapeutics is cutting back so dramatically, and more.
The need-to-know this morning
• Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around a class of targeted chemotherapy treatments called antibody-drug conjugates. STAT reporter Drew Joseph has more details on one of the largest biopharma licensing deals in recent years.
• A novel type of immunotherapy from Amgen generated strong response rates in patients with advanced small cell lung cancer, results that could lead to the approval of the drug.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect